Enliven Therapeutics (Enliven Therapeutics) Interest Coverage : No Debt ⁽¹⁾ (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Enliven Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Enliven Therapeutics's Operating Income for the three months ended in Mar. 2024 was $-25.99 Mil. Enliven Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Enliven Therapeutics has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Enliven Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Enliven Therapeutics's Interest Coverage or its related term are showing as below:

ELVN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

ELVN's Interest Coverage is ranked better than
99.41% of 341 companies
in the Biotechnology industry
Industry Median: 144.99 vs ELVN: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Enliven Therapeutics Interest Coverage Historical Data

The historical data trend for Enliven Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Enliven Therapeutics Interest Coverage Chart

Enliven Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Interest Coverage

No Debt

Enliven Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Coverage	Get a 7-Day Free Trial							No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Enliven Therapeutics's Interest Coverage

For the Biotechnology subindustry, Enliven Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enliven Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enliven Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Enliven Therapeutics's Interest Coverage falls into.

Enliven Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Enliven Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Enliven Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-83.53 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Enliven Therapeutics had no debt ⁽¹⁾.

Enliven Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, Enliven Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-25.99 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Enliven Therapeutics had no debt ⁽¹⁾.

The higher the ratio, the stronger the company's Financial Strength is.

Enliven Therapeutics (NAS:ELVN) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Enliven Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Enliven Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Enliven Therapeutics (Enliven Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enliven Therapeutics Inc (NAS:ELVN) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

6200 Lookout Road, Boulder, CO, USA, 80301

Website

https://www.enliventherapeutics.com

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially best-in-class or first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases.

Executives

Anish Patel	officer: Chief Operating Officer	C/O ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301
Benjamin Hohl	officer: Chief Financial Officer	6200 LOOKOUT ROAD, BOULDER CO 80301
Joseph P Lyssikatos	director, officer: Chief Scientific Officer	6200 LOOKOUT ROAD, BOULDER CO 80301
Samuel Kintz	director, officer: President and CEO	ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301
Richard A. Heyman	director	5871 OBERLIN DRIVE, SUITE 150, SAN DIEGO CA 92121
5am Partners Vi, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Rishi Gupta	director, 10 percent owner	C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Andrew J. Schwab	director	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Helen Louise Collins	director	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Jake Bauer	director	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
5am Opportunities I, L.p.	10 percent owner	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Orbimed Genesis Gp Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Kush Parmar	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Vi, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107